Tests mirikizumab with or without tirzepatide in ulcerative colitis and excess weight
Tests mirikizumab alongside tirzepatide or placebo in adults with ulcerative colitis and overweight.
Plain-language title generated from the registry record
Registry title: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Key facts
- Where
- Aalst, Brussels, Kortrijk, Leuven, and Liège, BelgiumSee the 6 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderately to severely active ulcerative colitis who also have obesity or overweight. It tests mirikizumab given together with tirzepatide.
- Age
- 18 Years to 70 Years
- Sex
- All sexes can join.
- Disease stage
- Ulcerative colitis diagnosed at least 3 months before the start, with moderately to severely active disease (modified Mayo score 5 to 9 points and endoscopic subscore 2 to 3).
- Earlier treatment
- People must have had an inadequate response, loss of response or intolerance to at least 1 conventional medicine (oral corticosteroids, azathioprine or 6-mercaptopurine, or 5-aminosalicylates), and/or to advanced therapy such as a biologic or JAK inhibitor.
- Biomarker or test result
- Obesity (BMI 30 kg/m2 or more), or overweight (BMI 27 kg/m2 to under 30 kg/m2) with at least 1 weight-related condition such as hypertension, Type 2 Diabetes Mellitus, dyslipidemia, obstructive sleep apnea or cardiovascular disease.
Main reasons for not taking part
- Crohn's disease, unclassified IBD or primary sclerosing cholangitis
- Past or planned bowel resection or intestinal or intra-abdominal surgery
- Type 1 Diabetes Mellitus or insulin-treated Type 2 Diabetes Mellitus
- Severe hypoglycemia or hypoglycemia unawareness in the 6 months before screening
- Body weight change of more than 5% in the 3 months before screening
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06937086, who can take part
Where in Belgium
- AZORG Campus Aalst-MoorselbaanAalst, BelgiumContact: Stijn Vanden Branden (principal investigator)Taking people
- Université Libre de Bruxelles - Hôpital ErasmeBrussels, BelgiumContact: Denis Franchimont (principal investigator)Taking people
- AZ Groeninge Campus KennedylaanKortrijk, BelgiumContact: Wouter Van Moerkercke (principal investigator)Taking people
- UZ LeuvenLeuven, BelgiumContact: João Guedelha Sabino (principal investigator)Taking people
- Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart TilmanLiège, BelgiumContact: Edouard Louis (principal investigator)Taking people
- Clinical Chc MontlégiaLiège, BelgiumContact: Arnaud Colard (principal investigator)Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT06937086EU 2024-520209-38-00
- Record updated
- 4 November 2026
- Original description
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight.Read full original descriptionShow less
A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight.
Participation in this study will last up to 61 weeks, including 52 weeks of treatment.
Inclusion: Have had an established diagnosis of UC for ≥3 months before baseline which includes endoscopic evidence of UC and a histopathology report that supports a diagnosis of UC; Have moderately to severely active UC as defined by a modified Mayo score (mMS) of 5 to 9 points and endoscopic subscore (ES) of 2 to 3 (confirmed by central review) within 21 days before baseline; Participants with a history of UC for greater than or equal to 8 years who have had a surveillance colonoscopy completed within 1 year prior to baseline must have documented negative results for colorectal dysplasia and cancer; Have obesity, [body mass index (BMI) 30 kilograms per meter squared (kg/m2)]; Have overweight (BMI ≥27 kg/m2 to <30 kg/m2) and in the presence of at least 1 of these weight-related comorbid conditions:; hypertension; Type 2 Diabetes Mellitus (T2DM); dyslipidemia; obstructive sleep apnea, or; cardiovascular disease; Have an inadequate response to, loss of response to, or intolerance to at least 1 of the conventional medication: oral corticosteroids, oral azathioprine (AZA) or 6-mercaptopurine (6-MP), or oral 5-aminosalicylates (for example, mesalamine, sulfasalazine, olsalazine, and balsalazide) and/or who have an inadequate response to or a loss of response to, or are intolerant to advanced therapy for UC, defined as: a biologic or biosimilar medication such as anti-tumor necrosis factor (TNF) antibodies; anti-integrin antibodies, Janus kinase (JAK) inhibitors such as tofacitinib or upadacitinib, sphingosine 1-phosphate receptor 1inhibitors such as etrasimod or ozanimod, or anti-interleukin(IL)-12p40 antibodies, for example, ustekinumab.
Exclusion: Have had or will need bowel resection or intestinal or intra-abdominal surgery; Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to screening; Have a self-reported change in body weight greater than 5% (gain or reduction) within 3 months prior to screening; Have a current diagnosis of:; Crohn's disease; inflammatory bowel disease (IBD) unclassified (formerly known as indeterminate colitis), or; primary sclerosing cholangitis; Have a diagnosis of Type 1 Diabetes Mellitus (T1DM) or have insulin-treated T2DM; Have a current or recent acute, active infection; Have evidence of toxic megacolon, or stricture or stenosis within the colon that cannot be traversed by a sigmoidoscope or colonoscope.